Compugen Ltd.
Compugen Ltd. is a biotechnology company that focuses on the discovery and development of therapeutic and diagnostic products. The company is headquartered in Holon, Israel, and operates in the fields of immuno-oncology, oncology, and autoimmune diseases.
History[edit | edit source]
Compugen Ltd. was founded in 1993 by Dr. Eli Mintz and Dr. Simchon Faigler. The company initially focused on computational biology and bioinformatics, leveraging its proprietary predictive discovery platforms to identify novel drug targets and biomarkers.
Technology[edit | edit source]
Compugen utilizes a unique computational predictive discovery platform that integrates various biological data sources to identify novel drug targets and biomarkers. This platform is designed to accelerate the drug discovery process by predicting the potential efficacy and safety of new therapeutic candidates.
Therapeutic Areas[edit | edit source]
Compugen's primary focus areas include:
- Immuno-oncology: Developing therapies that harness the body's immune system to fight cancer.
- Oncology: Targeting various types of cancer with novel therapeutic approaches.
- Autoimmune diseases: Discovering treatments for diseases where the immune system attacks the body's own tissues.
Pipeline[edit | edit source]
Compugen has a robust pipeline of therapeutic candidates in various stages of development. Some of the key candidates include:
- COM701: An anti-PVRIG antibody for the treatment of solid tumors.
- COM902: An anti-TIGIT antibody for the treatment of various cancers.
- CGEN-15001T: A novel immune checkpoint inhibitor.
Collaborations and Partnerships[edit | edit source]
Compugen has established several strategic collaborations and partnerships with leading pharmaceutical companies and research institutions to advance its drug discovery and development efforts. Notable partners include Bristol-Myers Squibb and Bayer.
Leadership[edit | edit source]
The company's leadership team comprises experienced professionals from the biotechnology and pharmaceutical industries. The current CEO is Dr. Anat Cohen-Dayag, who has been with the company since 2002.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This biotechnology article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
